Anticonvulsant profile and teratogenicity of 3,3-dimethylbutanoylurea: A potential for a second generation drug to valproic acid

Epilepsia

Volumn 49, Issue 7, 2008, Pages 1202-1212

  Shimshoni, Jakob Avi ^a   Yagen, Boris ^a,b   Pessah, Neta ^a   Wlodarczyk, Bogdan ^c   Finnell, Richard H ^c   Bialer, Meir ^a,b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Anticonvulsants; Maximal electroshock seizure test; Pharmacokinetics; Subcutaneous pentylentetrazole seizure test; Teratogenicity

Indexed keywords

3,3 DIMETHYLBUTANOYLUREA; ANTICONVULSIVE AGENT; BICUCULLINE; ISOVALEROYLUREA; PENTETRAZOLE; PICROTOXIN; PIVALOYLUREA; VALPROIC ACID; VALPROIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; ELECTRIC SHOCK; EMBRYOTOXICITY; EPILEPSY; FEMALE; HIPPOCAMPUS; KINDLING; MALE; MOUSE; MOUSE STRAIN; NEURAL TUBE DEFECT; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; RAT; SEIZURE; TERATOGENICITY;

ANIMALS; ANTICONVULSANTS; BEHAVIOR, ANIMAL; ELECTRODES, IMPLANTED; HALF-LIFE; HIPPOCAMPUS; KINDLING, NEUROLOGIC; MALE; MICE; NEURAL TUBE DEFECTS; PENTYLENETETRAZOLE; RATS; RATS, SPRAGUE-DAWLEY; TERATOGENS; UREA; VALPROIC ACID;

EID: 47249142849     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2008.01624.x     Document Type: Article

References (47)

1. Baillie T 1992) Metabolism of valproate to hepatotoxic intermediates. Pharm Weekbl 14 : 122 125.
2. Barton ME, Klein BD, Wolf HH, White SH 2001) Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 47 : 217 227.
3. Bialer M 1991) Clinical pharmacology of valpromide. Clin Pharmacokinet 20 : 114 122.
4. Bialer M, Haj Yehia A, Badir K, Hadad S 1994). Can we develop improved derivatives of valproic acid? Pharm World Sci 16 : 2 6.
5. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T 2007) Progress report on new antiepileptic drugs: a summary of the eighth Eilat conference on new antiepileptic drugs (EILAT VIII). Epilepsy Res 73 : 1 52.
6. Bialer M, Yagen B 2007) Valproic acid: second generation. Neurotherapeutics 4 : 130 137.
7. Blotnik S, Bergman F, Bialer M 1996) Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats. Drug Metab Dispos 24 : 560 564.
8. Dar MS, Fakouhi T 1974) Studies on some aspects of the neuropharmacology of butylurea. Arch Int Pharmacodyn 208 : 204 212.
9. Dar MS 1976) Studies on the neuropharmacology of tert-butylurea in mice. Arch Int Pharmacodyn 219 : 103 115.
10. Finnell RH, Bennett GD, Karras SB, Mohl VK 1988) Common hierarchies of susceptibility to the induction of neural tube defects by valproic acid and its 4-propyl-4-pentenoic acid metabolite. Teratology 38 : 313 320.
11. Finnell RH, Wlodarczyk BJ, Craig JC, Piedrahita JA, Bennett GD 1997) Strain-dependent alterations in the expression of folate pathway genes following teratogenic exposure to valproic acid in a mouse model. Am J Med Genet 70 : 303 311.
12. Gerber N, Dickneson RG, Harland RC, Lynn RK, Houghton D, Antonias JI, Schimaschok JC 1979) Reye-like syndrome associated with valproic acid therapy. J Pediatr 95 : 142 144.
13. Haj-Yehia A, Bialer M 1989) Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity. Pharm Res 6 : 683 689.
14. Haj-Yehia A, Bialer M 1990) Structure-pharmacokinetic relationships in a series of short fatty acid amides that possess anticonvulsant activity. J Pharm Sci 79 : 719 724.
15. Haj-Yehia A, Hadad S, Bialer M 1992) Pharmacokinetic analysis of the structural requirements for forming stable analogues for valpromide. Pharm Res 9 : 1058 1063.
16. Harden CL 2007) Pregnancy and epilepsy. Semin Neurol 27 : 453 459.
17. Holmes GL 2007) Animal models studies application to human patients. Neurology 69 : 28 32.
18. Isoherranen N, Yagen B, Bialer M 2003a) New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet? Curr Opin Neurol 16 : 203 211.
19. Isoherranen N, Yagen B, Woodhead JH, Spiegelstein O, Blotnik S, Wilcox SK, Finnell RH, Bennett DG, White SH, Bialer M 2003b) Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents. Br J Pharmacol 138 : 602 613.
20. Isoherranen N, White SH, Klein BD, Roeder M, Woodhead JH, Schuring V, Yagen B, Bialer M 2003c) Pharmacokinetic-pharmacodynamic relationship of (2S, 3S)-valnoctamide and its stereoisomer (2R, 3S)-valnoctamide in rodent models of epilepsy. Pharm Res 20 : 1293 1301.
21. Johnson PC, Cressman WA, Driscoll BS 1972) Absorption and excretion of a monoureide hypnotic, Capuride. Clin Pharmacol Ther 13 : 377 379.
22. Kaneko S, Kondo T 1995) Antiepileptic agents and birth defects. CNS Drugs 3 : 41 55.
23. Koenig SA, Siemed H, Blaker F, Boenigk E, Gross-Selbeck G, Hanefel F, Haas N, Kohler B, Koelfen W, Korinthenber R, Scheffner D 1994) Severe hepatotoxicity during valproate therapy: an updated report of eight fatalities. Epilepsia 35 : 1005 1015.
24. Koenig SA, Buesing D, Longin E, Oehring R, Häussermann P, Kluger G, Lindmayer F, Hanusch R, Degen I, Kuhn H, Samii K, Jungck A, Brückner R, Seitz R, Boxtermann W, Weber Y, Knapp R, Richard HH, Weidner B, Kasper JM, Haensch CA, Fitzek S, Hartmann M, Borusiak P, Müller-Deile A, Degenhardt V, Korenke GC, Hoppen T, Specht U, Gerstner V 2006) Valproic acid-induced hepatopathy: nine new Fatalities in Germany from 1994 to 2003. Epilepsia 47 : 2027 2031.
25. Kudo K, Kiyoshima A, Ohtsuka Y, Ikeda N 2003) Simultaneous determination of bromvalerylurea and allylisopropylacetylurea in human blood and urine by Gas Chromatography-Mass Spectrometry. J Chromatogr B 791 : 171 177.
26. Lindhout D, Schmidt D 1986) In-utero exposure to valproate and neural tube defects. Lancet 1 : 1392 1393.
27. Lothman EW, Salerno RA, Perlin JB, Kaiser DL 1988) Screening and characterization of antiepileptic drugs with rapidly recurring hippocampal seizures in rats. Epilepsy Res 2 : 367 379.
28. Mrongovius RI 1975) Structure-activity correlations for central depressant acylureas and alkylureas. Eur J Med Chem 10 : 474 479.
29. Nau H, Loscher W 1986) Pharmacological evaluation of various metabolites and analogoues of valproic acid: teratogenic potencies in mice. Fundam Appl Toxicol 6 : 669 676.
30. Nau H, Hauck RS, Ehlers K 1991) Valproic acid induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol Toxicol 69 : 310 321.
31. Perucca E, French J, Bialer M 2007) Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol 6 : 793 804.
32. Racine RJ 1972) Modification of seizure activity by electrical stimulation, II: motor seizure. Electroencephalogr Clin Neurophysiol 32 : 281 294.
33. Rettie AE, Rettenmeir AW, Howald WN, Baillie TA 1987) Cytochrom P450 catalyzed formation of 4-ene-VPA, a toxic metabolite of valproic acid. Science 235 : 890 893.
34. Rowland M, Tozer TN 1995) Clinical pharmacokinetics: concepts and application. 3rd ed. Williams & Wilkins, Philadelphia.
35. Sankar R 2007) Teratogenicity of antiepileptic drugs: role of drug metabolism and pharmacogenomics. Acta Neurol Scand 116 : 65 71.
36. Shah VP, Midha KM, Findlay FWA, Hill HM, Hulse JD, McGilvelli IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT, Yakobi A 2000) Bioanalytical method validation-a revisit with a decade of progress. Pharm Res 17 : 1551 1557.
37. Shimshoni JA, Bialer M, Wlodarczyk B, Finnell RH, Yagen B 2007) Potent anticonvulsant urea derivatives of valproic acid constitutional isomers. J Med Chem 50 : 6419 6427.
38. Smith M, Wilcox KS, White HS 2007) Discovery of antiepileptic drugs. Neurotherapeutics 4 : 12 17.
39. Spielman MA, Geiszler AO, Close WJ 1948) Anticonvulsant drugs, II. Some acylureas. JACS 70 : 4189 4191.
40. Sobol E, Bialer M, Yagen B 2004) Tetramethylcyclopropyl analogue of a leading antiepileptic drug, valproic acid. Synthesis and evaluation of anticonvulsant activity of its amide derivatives. J Med Chem 47 : 4316 4326.
41. Sobol E, Yagen B, Winkler I, Britzi M, Gibson D, Bialer M 2005) Pharmacokinetics and metabolism of a new potent antiepileptic drug, 2,2,3,3-tetramethylcyclopropanecarbonylurea, in rats. Drug Metab Dispos 33 : 1538 1546.
42. Sobol E, Yagen B, White HS, Wilcox KS, Lamb JG, Pappo O, Wlodarczyk BJ, Finnell RH, Bialer M 2006) Preclinical evaluation of 2,2,3,3- tetramethylcyclopropanecarbonylurea, a novel, second generation to valproic acid, antiepileptic drug. Neuropharmacology 51 : 933 946.
43. Stoughton RW, Dickison HL, Fitzhugh G 1939) Diacetylureas. II. Preparation and properties of diacylureas derived from branched aliphatic acids. JACS 61 : 408 410.
44. Tomson T, Battino D 2005) Teratogenicity of antiepileptic drugs: state of the art. Curr Opin Neurol 18 : 135 140.
45. Tomson T, Battino D 2007) Teratogenic effects of antiepileptic drugs. Seizure 17 : 166 171.
46. White HS, Woodhead JH, Wilcox KS, Stables JP, Kupferberg HJ, Wolf HH 2002) Discovery and preclinical development of antiepileptic drugs. In Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds) Antiepileptic drugs. 5th ed. Lippincott Williams & Wilkins Publishers, New York, pp. 36 48.
47. Zimmerman HJ, Ishak KG 1982) Valproate-induced hepatic injury: analysis of 23 fatal cases. Hepatology 2 : 591 597.